date/time interval
- October 16, 2024 - October 15, 2026
Randomized multicenter phase II trial of neoadjuvant chemotherapy plus cemiplimab vs SBRT 8Gy x 3 plus cemiplimab for c-stage IB-IIIA/IIIB (resectable) NSCLC (2024 Winn CDA)
Grant
Overview
awarded by
administered by
sponsor award ID
- VCU 242454-01
Affiliation
contributor
- Villena-Vargas, Jonathan Principal Investigator (Subaward) 2024 - 2027